Vimseltinib is the first and only therapy with marketing authorization for the treatment of TGCT in the European Union Ono Pharmaceutical Co.,...
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corp...
AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, annou...
Proprietary process reduces development timelines from 18 months to as little as 3, eliminates reliance on traditional plastic flatware, and offers rap...
NurExone Biologic Inc., a biopharmaceutical innovator in exosome-based regenerative therapies, is pleased to announce that its U.S. subsidiary, Exo...
Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa’s...
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its AbZelectPRO™ cell line deve...
Targeted proteomics panel delivers absolute quantification of key and emerging biomarkers in one scalable assay Thermo Fisher Scientific Inc., the world...
Beckman Coulter Life Sciences, a Danaher company and a global leader in laboratory automation and innovation, announces the launch of its new IR820 and I...
Gene Solutions, a leader in mitochondrial dysfunction genomics and CNS drug discovery, announces the publication of its platform technology patent. The a...
The founder and long-standing CEO of PlasmidFactory GmbH, Dr. Martin Schleef, was honored in Düsseldorf with the Innovation Award 2025 of the State ...
Collaboration will help reduce stable cell line development timelines in AAV genomic medicine development and ultimately also shorten development timeline ...
Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune d...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...
© 2025 Biopharma Boardroom. All Rights Reserved.
